These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38341128)

  • 1. Bridging and Validation of the Specific Graves Ophthalmopathy Quality of Life Questionnaire With Health State Utility Values.
    Smith TJ; Cockerham K; Barretto N; Hirst A; Oliver L; Enstone A; Brandolini G; Taylor SD; Holt RJ
    Endocr Pract; 2024 May; 30(5):470-475. PubMed ID: 38341128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility Assessment of Moderate to Severe Thyroid Eye Disease Health States.
    Smith TJ; Cockerham K; Lelli G; Choudhary C; Taylor S; Barretto N; Enstone A; Oliver L; Lynch J; Holt RJ
    JAMA Ophthalmol; 2023 Feb; 141(2):159-166. PubMed ID: 36580313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy of Teprotumumab in Thyroid Eye Disease: Follow-Up Outcomes in Three Clinical Trials.
    Kahaly GJ; Subramanian PS; Conrad E; Holt RJ; Smith TJ
    Thyroid; 2024 Jul; 34(7):880-889. PubMed ID: 38824618
    [No Abstract]   [Full Text] [Related]  

  • 5. Teprotumumab for the Treatment of Active Thyroid Eye Disease.
    Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ
    N Engl J Med; 2020 Jan; 382(4):341-352. PubMed ID: 31971679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teprotumumab for the treatment of thyroid eye disease.
    Fallahi P; Ragusa F; Paparo SR; Elia G; Balestri E; Mazzi V; Patrizio A; Botrini C; Benvenga S; Ferrari SM; Antonelli A
    Expert Opin Biol Ther; 2023 Feb; 23(2):123-131. PubMed ID: 36695097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of thyroid eye disease: quality-of-life questionnaire (TED-QOL) in Korean patients.
    Son BJ; Lee SY; Yoon JS
    Can J Ophthalmol; 2014 Apr; 49(2):167-73. PubMed ID: 24767223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease.
    Fayers T; Dolman PJ
    Br J Ophthalmol; 2011 Dec; 95(12):1670-4. PubMed ID: 21951566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease.
    Men CJ; Amarikwa L; Pham B; Sears C; Clauss K; Lee BW; Lee WW; Pasol J; Ugradar S; Shinder R; Cockerham K; Wester S; Douglas R; Kossler AL
    Ophthalmic Plast Reconstr Surg; 2024 May-Jun 01; 40(3):276-285. PubMed ID: 37972960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study.
    Douglas RS; Kahaly GJ; Ugradar S; Elflein H; Ponto KA; Fowler BT; Dailey R; Harris GJ; Schiffman J; Tang R; Wester S; Jain AP; Marcocci C; Marinò M; Antonelli A; Eckstein A; Führer-Sakel D; Salvi M; Sile S; Francis-Sedlak M; Holt RJ; Smith TJ
    Ophthalmology; 2022 Apr; 129(4):438-449. PubMed ID: 34688699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of quality of life in patients with Graves orbitopathy and its influencing factors].
    Weng CY; Li ZF; Hu SD; Luo YS; Feng XT; Zhong Q; Zhang Q; Shen J
    Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):577-583. PubMed ID: 31365979
    [No Abstract]   [Full Text] [Related]  

  • 12. Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States.
    Cockerham KP; Padnick-Silver L; Stuertz N; Francis-Sedlak M; Holt RJ
    Ophthalmol Ther; 2021 Dec; 10(4):975-987. PubMed ID: 34478126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of quality of life in patients with Graves´ ophthalmopathy, before and after orbital decompression.
    Iacobæus L; Sahlin S
    Orbit; 2016 Jun; 35(3):121-5. PubMed ID: 27159575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity.
    Douglas RS; Couch S; Wester ST; Fowler BT; Liu CY; Subramanian PS; Tang R; Nguyen QT; Maamari RN; Ugradar S; Hsu K; Karon M; Stan MN
    J Clin Endocrinol Metab; 2023 Dec; 109(1):25-35. PubMed ID: 37925673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing the usefulness of the GO-QOL in a UK hospital-treated population with thyroid eye disease in the CIRTED trial.
    Dietrich A; Taylor P; White P; Wilson V; Uddin J; Lee RWJ; Dayan C; Jackson S;
    Psychol Health Med; 2018; 23(sup1):1341-1355. PubMed ID: 30092670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teprotumumab: A Review in Thyroid Eye Disease.
    Nie T; Lamb YN
    Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Related quality of life questionnaire specific to dysthyroid ophthalmopathy evaluated in a population of patients with Graves' disease.
    Delfino LC; Zunino A; Sapia V; Croome MDCS; Ilera V; Gauna AT
    Arch Endocrinol Metab; 2017; 61(4):374-381. PubMed ID: 28225858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing quality of life in Taiwanese patients with Graves' ophthalmopathy.
    Lin IC; Lee CC; Liao SL
    J Formos Med Assoc; 2015 Nov; 114(11):1047-54. PubMed ID: 24434244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity and responsiveness of the patient-reported TED-QOL to rehabilitative surgery in thyroid eye disease.
    Fayers T; Fayers PM; Dolman PJ
    Orbit; 2016 Dec; 35(6):328-334. PubMed ID: 27599688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.